BIT Capital GmbH Boosts Holdings in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS)

Key Points

• BIT Capital GmbH increased its stake in COMPASS Pathways PLC by 112.9% during the first quarter, owning 246,320 shares worth approximately $704,000.
• Analysts have a mixed outlook on COMPASS Pathways, with a current average rating of "Moderate Buy" and price targets ranging from $6.00 to $45.00.
• COMPASS Pathways reported a loss of ($0.38) EPS for the last quarter, missing analyst estimates, while facing an anticipated full-year EPS of ($2.33).

BIT Capital GmbH lifted its position in shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 112.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 246,320 shares of the company's stock after purchasing an additional 130,623 shares during the period. BIT Capital GmbH owned 0.27% of COMPASS Pathways worth $704,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. ARK Investment Management LLC boosted its position in shares of COMPASS Pathways by 4.0% in the first quarter. ARK Investment Management LLC now owns 1,804,803 shares of the company's stock valued at $5,162,000 after acquiring an additional 68,601 shares during the period. Cerity Partners LLC acquired a new position in shares of COMPASS Pathways during the 1st quarter worth approximately $29,000. Alps Advisors Inc. increased its holdings in shares of COMPASS Pathways by 19.7% during the first quarter. Alps Advisors Inc. now owns 66,231 shares of the company's stock worth $189,000 after purchasing an additional 10,899 shares during the period. Flagship Harbor Advisors LLC increased its holdings in shares of COMPASS Pathways by 27.7% during the first quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company's stock worth $41,000 after purchasing an additional 3,134 shares during the period. Finally, GAMMA Investing LLC raised its position in shares of COMPASS Pathways by 93.6% in the first quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock valued at $30,000 after buying an additional 5,003 shares in the last quarter. 46.19% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. HC Wainwright dropped their price objective on COMPASS Pathways from $45.00 to $40.00 and set a "buy" rating for the company in a report on Monday. Canaccord Genuity Group reaffirmed a "buy" rating and set a $15.00 price target on shares of COMPASS Pathways in a report on Friday, August 1st. Evercore ISI restated an "in-line" rating and set a $6.00 target price (down from $11.00) on shares of COMPASS Pathways in a research note on Monday, June 23rd. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $12.00 price target on shares of COMPASS Pathways in a report on Tuesday, May 27th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $16.29.

COMPASS Pathways Trading Up 0.2%

NASDAQ CMPS traded up $0.01 during mid-day trading on Thursday, reaching $4.37. 241,478 shares of the stock were exchanged, compared to its average volume of 1,823,582. COMPASS Pathways PLC Sponsored ADR has a one year low of $2.25 and a one year high of $8.54. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.82 and a quick ratio of 8.82. The stock has a 50 day simple moving average of $4.01 and a 200-day simple moving average of $3.82. The stock has a market cap of $419.07 million, a P/E ratio of -2.36 and a beta of 2.17.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.01). On average, analysts anticipate that COMPASS Pathways PLC Sponsored ADR will post -2.33 EPS for the current year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.